Chinese General Practice ›› 2023, Vol. 26 ›› Issue (36): 4575-4580.DOI: 10.12114/j.issn.1007-9572.2023.0176

Special Issue: 新型冠状病毒肺炎最新文章合集 COVID-19疫情防控研究

• Article • Previous Articles     Next Articles

The Experience of Inhaled COVID-19 Vaccination among First-line Medical Staff in Epidemic Prevention Aged≥18 Years in Guiyang City: a Qualitative Study


  1. 1. Department of Preventive Health, Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang 550002, China
    2. Dean's Office of Guizhou Nursing Vactional College, Guiyang 550004, China
    3. Nursing Department, Guizhou Provincial People's Hospital, Guiyang 550001, China
    4. School of Nursing, Guizhou University of Traditional Chinese Medicine, Guiyang 550001, China
    5. Emergency Department, Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang 550002, China
  • Received:2023-02-15 Revised:2023-04-12 Published:2023-12-20 Online:2023-05-08
  • Contact: BAI Xiaoling



  1. 1.550002 贵州省贵阳市,贵州中医药大学第二附属医院预防保健科
    2.550004 贵州省贵阳市,贵州护理职业技术学院院长办公室
    3.550001 贵州省贵阳市,贵州省人民医院护理部
    4.550001 贵州省贵阳市,贵州中医药大学护理学院
    5.550002 贵州省贵阳市,贵州中医药大学第二附属医院急诊科
  • 通讯作者: 柏晓玲
  • 作者简介:
  • 基金资助:
    贵州省科技计划项目(黔科合支撑〔2021〕一般035); 贵州中医药大学第二附属医院青苗科研启动基金项目(GZEYK-Y〔2022〕17号)



Inhaled recombinant COVID-19 vaccine (type 5 adenoviral vector) (hereinafter referred to as the inhaled COVID-19 vaccine) is the first approved inhaled COVID-19 vaccine in China, with the advantages of good immunity, painlessness, and higher accessibility, which has been included in the WHO Emergency Use Listing and China's list of second-dose booster immunization vaccines. The real-world application of this vaccine deserves more attention due to the poor understanding of it by the public.


To understand the real experience in depth of first-line medical staff in epidemic prevention aged≥18 years in Guiyang city who received inhaled COVID-19 vaccine, so as to provide a reference for the promotion of this type of vaccine.


The recipients who completed the emergency vaccination with inhaled COVID-19 vaccine at a vaccination site of Guiyang city in October 2022 were selected as research subjects based on the the principle of booster immunization by using purposive sampling method. The sample size was determined by interviewing until no new case emerged which was data saturation. A total of 17 recipients were interviewed in this study. Semi-structured interviews were conducted with the research subjects, face-to-face interviews were conducted to understand the vaccination experience at that time firstly, and telephone interviews were conducted 5-7 days after vaccination. The Colaizzi seven-step analysis method was used for the data collection and analysis.


A total of five themes were summarized including the convenience of vaccination, good vaccination experience, light psychological burden, low vaccine hesitancy and uncertain protective effect. The convenience of vaccination includes simple and time-saving vaccination process, fast vaccination speed, low cost, and no interruption of nucleic acid testing; the good vaccination experience includes comfortable feeling of vaccination, harmonious observation atmosphere, fewer adverse reactions, and no interference with daily life; light psychological burden includes reduction of tension and anxiety of vaccination, better mental health maintenance, non-invasive vaccination and elimination of vaccination fears; low vaccine hesitancy includes high vaccination accessibility, increase of vaccine acceptance, increase of public perception of epidemic outbreak risk; uncertain protective effect includes uncertain which vaccination method provides better protection between injection and inhalation, whether inhaled COVID-19 vaccine has a good protective effect against variant strains.


Inhaled COVID-19 vaccine is convenient to administer with fewer adverse reactions, which is highly accepted by first-line medical staff in epidemic prevention aged≥18 years in Guiyang city with good experience.

Key words: COVID-19, SARS-CoV-2, Adenovirus vaccines, COVID-19 vaccines, Immunization, secondary, Inhalants, Qualitative research, Guiyang







采用目的抽样法,根据加强免疫接种原则选取2022年10月在贵阳市某接种点完成紧急接种吸入用新冠疫苗的受种者作为研究对象,样本量的确定以访谈到没有新的信息出现,即访谈资料饱和为止,本研究共访谈了17位受种者。对研究对象进行半结构式访谈,首先采用面对面访谈了解当时的接种体验,并约定接种后5~7 d进行电话访谈,运用Colaizzi七步分析法对资料进行整理分析。





关键词: 新型冠状病毒感染, 新型冠状病毒, 腺病毒疫苗, COVID-19疫苗, 免疫接种,加强, 吸入剂, 质性研究, 贵阳